Forward Citations = 79

Loading Chart...

7 inventors (with patents filed for the assignee):

Samuel Ray Denmeade (7 out of 24 patents)

John Tod Isaacs (7 out of 21 patents)

Hans Lilja (2 out of 11 patents)

4. Xiong Fu (1 out of 4 patents)

5. John K Lynch (1 out of 3 patents)

6. Jeff Hutchison (1 out of 4 patents)

7. Kevin Kunnen (1 out of 5 patents)

8 patents: Sort by Forward Citations

1. 9446141 - Methods of producing cancer compounds (2016-09-20),

2. 8957016 - Tumor activated prodrugs (2015-02-17),

3. 8822406 - Tumor activated prodrugs (2014-09-02),

4. 8669231 - Activation of peptide prodrugs by hK2 (2014-03-11),

5. 7906477 - Activation of peptide prodrugs by hK2 (2011-03-15),

6. 7767648 - Tissue specific prodrugs (2010-08-03),

7. 7635682 - Tumor activated prodrugs (2009-12-22),

8. 7468354 - Tissue specific prodrugs (2008-12-23),

Genspera, Inc. is a biotechnology company focused on developing and commercializing novel treatments for cancer. Their lead product candidate, AzaSite, is a targeted therapy designed to selectively kill cancer cells while leaving healthy cells unharmed. Genspera's innovative approach has the potential to revolutionize cancer treatment and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

8 Patents

#80 in San Antonio, TX

#2,213 in Texas

#34,852 in US

San Antonio, TX, United States of America

Genspera, Inc.